FDA or­ders a par­tial hold on Epizyme’s lead can­cer drug tazeme­to­stat fol­low­ing T-cell lym­phoma case

Epizyme $EPZM is in some hot wa­ter this evening af­ter the biotech re­vealed a par­tial clin­i­cal hold on its cru­cial pro­gram for tazeme­to­stat.

The Cam­bridge, MA-based biotech was forced to slam the brakes on any en­roll­ment for its clin­i­cal tri­als of the drug for now as in­ves­ti­ga­tors sort out a pe­di­atric case of sec­ondary T-cell lym­phoma.

In­vestors didn’t like it. The biotech’s shares tanked 18% in af­ter-mar­ket trad­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.